MRIMS Journal of Health Sciences 2016;4(3) pissn: , eissn:
|
|
- Franklin Wilkins
- 6 years ago
- Views:
Transcription
1 MRMS Journal of Health Sciences 2016;4(3) pssn: , essn: Original Article Drug Sensitivity Pattern among Category Relapse Cases of Pulmonary Tuberculosis and ts Correlation with Pre- treatment Sputum and Radiological Status. Narendra Kumar Narahari 1, Sudhir Kumar Vujhini 2 1 Assistant Professor, Department of Respiratory Medicine, 2 Associate Professor, Department of Transfusion Medicine, Nizam s nstitute of Medical Sciences, Hyderabad, Telangana, ndia. Corresponding Author: Dr. Narendra Kumar Narahari Received: drnarendrajipmer@gmail.com Accepted: Abstract: Background: An increased incidence of drug resistance is seen even after active implementation of directly observed treatment short course (DOTS). Early diagnosis of such cases can be improved by performing DST (drug sensitivity test) in all relapse cases. Objective: To know the drug sensitivity pattern and emergence of drug resistance among the category relapse cases of pulmonary tuberculosis by culture of sputum & drug sensitivity. Material and methods: n this prospective analysis, we have studied the pattern of drug resistance met with in Mycobaclerium tuberculosis isolates obtained from 102 relapse cases who have completed category- treatment under DOTS. Results: A very high prevalence of MDR-TB (35.29%) is seen among the category relapse cases. An increased drug resistance among relapse cases correlated well with extensive disease with cavitation radiologically and heavy sputum bacillary load in their pre treatment status. Conclusions: We conclude that all relapse cases should be evaluated for sputum culture and drug sensitivity at the earliest to know about the sensitivity pattern before putting them on category 2. DOTS therapy needs to consider some individualization of treatment based on case specific circumstances, not routinely but atleast for those patients with very extensive disease with cavitation and heavy bacillary load in the sputum. Key words: Pulmonary Tuberculosis, treatment, sputum NTRODUCTON: Tuberculosis remains a major public health problem in ndia. ndia accounts for 1/4 th of the global incidence of tuberculosis and tops the list of 22 high tuberculosis burden countries. [1] Though multi drug therapy in tuberculosis in a well established and executed programme proved to be a major success, very often relapses occur in some of the treated cases in the programme. [2] Relapses are usually due to incomplete sterilization of tuberculosis lesions, [3] initial drug resistance patterns, irregularity of the treatment, inadequate treatment regimens and duration. [4] t was considered that relapse was caused by the drug sensitive organisms based on the bacteriological evaluation, but with the emergence of multidrug resistant strains and the changing trends of global resurgence of tuberculosis, a change in drug sensitive pattern within the relapses has been observed. [2] nadequate drug therapy, inadequate doses and lack of properly organized system to ensure effective treatment are the common causes for the development of drug resistance in the community and it reflects failure of National Tuberculosis Programmes. [4] The Global data showed that 32% of the relapse cases are actually MDR TB (multidrug-resistant tuberculosis). [5] With the alarming threat of XDR-TB (extremely drug resistant tuberculosis) and TDR-TB (totally drug resistant tuberculosis), and the increase in HV population the mortality rate is destined to increase, unless some urgent measures are taken up. Therefore, reduction in relapses cases who received revised national tuberculosis control programme (RNTCP) category treatment may also reduce the total number of MDR cases in MRMS Journal of Health Sciences, Vol. 4, No. 3, July-September 2016 Page 166 [6] ndia. n a country like ndia with high initial NH resistance, most experts and literature [4,6,7] recommend supervised daily regimen during intensive phase over thrice weekly treatment to reduce the risk of relapse and drug resistance. This approach should be highly individualized at least in patients with extensive disease with cavitation and heavy bacillary load as the evidence suggests. [8] MATERAL AND METHODS All patients coming to pulmonary medicine OP and pulmonary medicine ward in Government general hospital, Kurnool, who complain of cough for three weeks or more, with or without other symptoms suggestive of tuberculosis (viz. breathlessness, fever, chest pain, hemoptysis, and wheeze) after RNTCP treatment during the period January 2006 to December 2008 were evaluated. All these patients
2 had earlier received fully supervised short course chemotherapy under DOTS (Cat-).Among them 102 patients who fit into down cited selection criteria (Table 1) were taken for the study. Table: 1 showing Selection Criteria nclusion criteria Adult patients with pulmonary tuberculosis who have completed supervised short course chemotherapy under RNTCP (DOTS) for 6 months and presenting with Positive sputum smear samples and Clinical deterioration and /or Radiological worsening Exclusion criteria Pediatric patients Extra pulmonary tuberculosis patients Adult patients with pulmonary tuberculosis who took daily regimen of antitubercular drugs. Co-morbid conditions (corpulmonale, cardiac, renal diseases, liver cirrhosis Diabetes) HV Defaulters, treatment failures The relapse cases were evaluated clinically, radiologically and bacteriologically. The diagnosis of sputum positive pulmonary tuberculosis was done as per RNTCP diagnostic algorithm. Sputum specimens were also collected from these patients and transported to State Tuberculous Center, and/ or ravatham clinical laboratories, Hyderabad, for culture and sensitivity for mycobacterium tuberculosis, through a courier system. Complete Blood Picture, urinalysis, blood sugar, urea, creatinine, uric acid, and liver function tests were done in all cases. Culture of mycobacterium tuberculosis usually takes 6-8 weeks to become positive. Drug susceptibility testing of the first line antituberculous drugs (ATT) was done by absolute concentration method (MC, minimum inhibitory concentration) following the TRC protocol. Meanwhile patients were referred to District tuberculosis center (DTC) for continuation of DOTS under category- till their culture and sensitivity reports were obtained. Once the sensitivity reports were available, patients were treated with drug regimen decided on the basis of the drug susceptibility profile in the reports. Polyresistance was defined as resistance to two or more anti-tuberculosis drugs. Resistance to RF (Rifampicin) and NH (isoniazid), with or without resistance to any other drug was labelled as multidrug resistance or MDR-TB. RESULTS & DSCUSSON Table 2: Distribution of cases according to type, culture and drug sensitivity (NH: isoniazid, RF: rifampicin) Out of 102 relapse cases in our study, 75(73.52%) cases belong to the age group below 45 years who are in the economically productive age group and are the bread earners of the family. Mean age of the study group was Drug sensitivity pattern No. of cases Percentage of the total ( N = 102) Sputum smear % positive and culture negative Culture positive (Sputum smear positive) % NH + RF % (sensitive) Drug resistant % (Resistance) years. Mean age among male and female patients was and years respectively. 71 (69.60%) cases were males and 31 (30.39%) were female patients. Male to female ratio is 2:1. The most common clinical presentation was cough, fever and dyspnea, followed by loss of weight and appetite. Extensive disease with cavitation in the chest radiographs was found in 76 (74.50%) cases. Most of the relapses (87%) occurred within one year of stopping chemotherapy. 76 cases (74.50%) were culture positive and sputum smear positive and 26 (25.49%) were sputum smear positive and culture negative. Out of the 76 culture positive cases, 23 (22.54%) were both NH and RF sensitive. 53 (51.96%) out of 76 culture positive cases were drug resistant cases.(table 2). Among them, 37 (36.27%) are poly resistant and 36 (35.29%) patients are both NH and RF resistant. These were MDR TB cases. Single drug resistance was seen in 15.68% of the cases and mono resistance to NH and RF was seen in 2 (0.01%) and 14 (13.72%) of the cases. Resistance to each drug NH is 38.23%, and rifampicin is 35.29%, and that due to ethambutol and streptomycin is 15.68% and 10.78% (Table 3) Out of the 53 drug resistant cases, most of them 52(98.11%) had extensive disease with cavitation on their pre-treatment chest radiographs (i.e at the time of initiation of cat ). This pattern shows the distribution of resistance cases according to the severity of disease on their pre-treatment chest radiographs.(table 4) MRMS Journal of Health Sciences, Vol. 4, No. 3, July-September 2016 Page 167
3 Table 3: Distribution of drug resistant cases Drug sensitivity pattern No. of Percentag cases e of the total ( N = 102) Poly drug resistance % MDR TB ( NH % RF resistant) Single drug resistance % a NH ( soniazid) % b RF (Rifampicin) % Resistance to any V drug a Resistance to any H % b Resistance to any R % c Resistance to any E % d Resistance to any S % Table 4: Distribution of resistance cases according to the severity of disease on their pre-treatment chest X-rays X ray findings (at the time of initiation of cat ) Minimal disease without cavitation Extensive disease with cavitation No. of Percentage resistance of the total cases among ( N = 53) cat relapses % % MDR- TB: multi drug resistant tuberculosis, NH: isoniazid, RF: rifampicin, H: isoniazid, R: rifampicin, E: ethambutol, S: streptomycin Out of the 53 drug resistant cases, most of them 49(92.45%) had heavy bacillary load in the pre-treatment sputum smears. This pattern shows the distribution of resistance cases according to bacillary content in the pre-treatment sputum smears.(table 5) DSCUSSON: The present study gives information about the bacteriological status and prevalence of drug resistance among relapse cases who received DOTS category treatment. Relapse is defined as a TB patient who was declared cured or treatment completed by a physician, but who reports back to the health service and is now found to be sputum smear positive. The definition of relapse used in this study is from RNTCP. However relapse also refers to the circumference in which a patient becomes and remains culture negative while receiving therapy, but at some point after completion of therapy either becomes culture positive again or has clinical or radiological deterioration that is consistent with active tuberculosis including an appropriate response to re-treatment. [8] Rigorous efforts should be made to establish a diagnosis and to obtain microbiological confirmation of the relapse to enable testing for drug resistance. [8] Table 5: Distribution of resistance cases according to bacillary load in the sputum Pretreatment Sputum status (at the time of initiation of cat ) Heavy bacillary load Less bacillary load No. of resistance cases among cat relapses Percentage the total ( N = 53) % % Relapses in the present study occurred mainly in the cavitatory, far advanced disease and in those having delayed sputum conversion indicating a much higher mycobacterial population where naturally drug resistant strains are more likely. The relapse is usually due to quiescent bacterial population, which did not proliferate during the initial treatment. Selection of spontaneous resistant mutant bacilli among these dormant bacterial populations was not a possibility and for this reason it was theoretically accepted that relapse exhibits the same pattern of drug sensitivity as that of patients with initial tuberculosis. f the relapse occurred several years after the initial treatment, it was concluded that re-infection is more likely to cause the disease. However due to changing trends in the pattern of drug resistance during recent years, microbiological confirmation of relapse should be pursued vigorously by drug susceptibility tests. nadequate treatment and treatment duration which causes incomplete sterilization of tuberculous lesions [3] are the main causes for true relapse, along with host factors, disease and treatment related factors which add up to the menace. [8] There are indications that the initial bacterial content, the extent of disease at diagnosis (presence of cavitation, extent of disease in the chest X-ray) initially, the speed of sputum conversion, early response to therapy, amount of therapy administered (number of doses, duration of therapy, intermittency of therapy) influence the relapse. [8] n a study by panda etal, [2] more than threefold rise of poly resistance was seen in relapse cases, with MDR- TB seen in 13.7% of the relapse cases. Single drug resistance among the relapse cases was around 17%. The resistance to different primary drugs was Streptomycin (20.7%), soniazid (17.0%) and Rifampicin (28.3%) respectively. Similar to our observation 36% of MDR- TB is seen in cat relapse cases in a study by shahzad et al. [9] WHO-UALTD Global Project on Antituberculosis Drug Resistance Surveillance ( ) in ndia showed that MDR among new TB cases was 2.3% and in previously MRMS Journal of Health Sciences, Vol. 4, No. 3, July-September 2016 Page 168 of
4 treated patients was 17.2%. [10] Rajendra Prasad et al [11] in his review stated that acquired drug resistance in ndia varied from 6 to 100%. The data of acquired drug resistance in ndia of the various studies along with the present study is represented down below. (Table 6) Table 6: Acquired drug resistance in ndia. Study Any H% Any S% Any R% H+R% WHO- UATLD ( ) [10] Deivanayag am (2002) [12] Paramasivan et al (2002) [13] North Arcot (South) Raichur (South) Prasad et al (2003) [14] Paramasivan et al (2010) [15] Prasad et al (2012) [16] Present 38.23% 10.78% 35.29% 35.29% study The alarming rise of MDR-TB is a growing concern and its emergence can be prevented by effective treatment of all TB cases. [11] The aims of chemotherapy are not only to cure but also to reduce relapse rate and the duration of infectivity there by stopping the spread of infection to others. Based on a study by Chang et al [8] it was mentioned that standard thrice weekly intermittent regimens with fewer administered doses might still be cost effective in the absence of cavitation on initial chest x ray. However among the patients with positive pretreatment cultures and cavitation, meaningful reduction of relapse rate could be achieved by daily regimen and the risk be further reduced by prolonging the treatment. Furthermore, in my study drug resistance is seen in patients with extensive disease or cavitation in the initial chest X-rays in 98.11% (52 out of 53drug resistant cases). n patients with heavy bacillary load in the pre-treatment sputum smear, 92.45% showed drug resistance. (49 out of 53 drug resistant cases). t should be understood that in case of minimal disease without cavitation and less bacillary load, intermittent therapy may be effective. But in cases of extensive disease with cavitation and heavy bacillary load, their efficacy is still debatable. ntermittent therapy with fewer administered doses results in insufficient sterilization of persisters leading to high relapse rate in cases of extensive disease. [8] The most successful method of eliminating drug resistance is to prevent its emergence by ensuring that drug sensitive tuberculosis is treated aptly. Certain factors like extent of disease and initial bacillary content, presence of residual cavitation at the end of chemotherapy plays an important role and in evaluating the pattern of resistance among relapses. [8] t was recommended to administer daily regimen in intensive phase to achieve early sputum conversion and to reduce the emergence of drug resistant mutants in patients with heavy bacillary load as faster sterilization is expected when actively dividing bacilli are killed daily. Thereafter, to continue thrice weekly regimen to ensure sterilization of the lesions by eliminating slowly or intermittently growing bacilli which helps in assuring complete cure and prevention of relapses and drug resistance. [8] CONCLUSON: t is high time to review all the relapse cases by sputum culture and drug susceptibility tests to know about sensitivity pattern before putting them on Category 2. DOTS therapy needs to consider some individualization of treatment based on case specific circumstances, not routinely but atleast for those patients with very extensive disease with cavitation and heavy bacillary load in the sputum. [8] By revising the management strategies and establishment of laboratory services for adequate and timely diagnosis, one can prevent the spread of MDR-TB and its associated morbidity and mortality by choosing the correct regimen on the basis of DST results performed in the beginning. [11] REFERENCES: 1. RNTCP status report. TB ndia 2007 Chapter 1 Page 10-13, 22 WHO report Geneva Global tuberculosis control surveillance, planning and financing. 2. Panda BN, Jena J, Rai SP, Chatterji RS. Supervised chemotherapy in pulmonary tuberculosis and emergence of drug resistance in case of relapse. nd. J. Tub 2000; 47: Tripathy SP. Relapse in tuberculosis. nd.j.tub 1980; 28: Azhar GS. DOTS for TB relapse in ndia: A systematic review. Lung ndia 2012; 29: World health organization. Treatment of tuberculosis guidelines. 4 th ed. WHO/HTM/TB/ Availablefrom: hqlibdoc.who.int/publications/2010/ _eng.pdfSimilar, accessed on May27, De S. High relapse rate in RNTCP: An increasing concern and time to intervene. Lung ndia 2013; 30: Chang KC, Leung CC, Grosset J, Yew WW. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011; 66: Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment - related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004; 170: Shahzad M, Ayyaz S, Humayun GM, Kamran MH, Dogar LA, Shaheen MA etal. A comparision of drug resistance pattern in category- failure versus category- relapse pulmonary TB patients MRMS Journal of Health Sciences, Vol. 4, No. 3, July-September 2016 Page 169
5 attending a tertiary care hospital in south punjab, Pakistan. s WHO category ATT regimen appropriate? Pakistan journal of chest medicine 19.1(2015). 10. WHO-UALTD Global Project on Antituberculosis Drug Resistance Surveillance ( ). Fourth Global Report. 2008, updated Prasad R, Gupta N, Singh M. Multidrug resistant tuberculosis: trends and control. ndian J Chest Dis Allied Sci Oct-Dec; 56(4): Review. 12. Deivanayagam CN, Rajasekaran S, Venkatesan R,Mahilmaran A, Ahmed PR, Annadurai S, et al. Prevalence of acquired MDR-TB and HV coinfection. ndian J Chest Dis Allied Sci 2002;44: Paramasivan CN, Venkataraman P, Chandrashekhran V, Bhatt S, Narayanan PR. Surveillance of drug resistant in tuberculosis in two districts of south ndia. nt J Tuberc Lung Dis Source of Support: Nil. Conflict of nterest: None ;6: Prasad R, Suryakant, Mukerji PK, Gupta AK, Garg R, Rizvi DM, et al. Acquired drug resistance in patients of pulmonary tuberculosis attending a tertiary care center. nt J Tuberc Lung Dis 2003;11 (Suppl.):S3O Paramasivan CN, Rehman F, Wares F, Sundar Mohan N, Sundar S, Devi S, et al. First- and second-line drug resistance patterns among previously treated tuberculosis patients in ndia. nt J Tuberc Lung Dis 2010; 14: Prasad R, Verma SK, Garg R, Jain A, Anand SC, Hosmane GB, et al. Drug susceptibility pattern of Mycobacterium tuberculosis isolates from patients of Category- failure of pulmonary tuberculosis under directly observed treatment short-course from North ndia. Biosci Trends 2012; 6: Cite this article as: Narendra Kumar Narahari, Sudhir Kumar Vujhini. Drug Sensitivity Pattern Among Category Relapse Cases of Pulmonary Tuberculosis and ts Correlation With Pre- treatment Sputum And Radiological Status. MRMS J Health Sciences 2016;4(3): MRMS Journal of Health Sciences, Vol. 4, No. 3, July-September 2016 Page 170
Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More informationRole of RNTCP in the management MDR-TB
Kamdar DJ, Shah NA, Patel DJ, Parmarr H. Role of RNTCP in the management of MDR-TB. IAIM, 2015; 2(7): 1-5. Original Research Article Role of RNTCP in the management of MDR-TB Deepali J Kamdar 1, Neha A
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Lancelot Pinto is a
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationEffectiveness of DOTS regime in terms of cure, failure, default and relapse in the treatment of TB patients
International Journal of Advances in Medicine Jahnavi K et al. Int J Adv Med. 2018 Feb;5(1):170-174 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20180079
More informationTB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)
TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationIMPACT OF IMPROVED TREATMENT SUCCESS ON THE PREVALENCE OF TB IN A RURAL COMMUNITY BASED ON ACTIVE SURVEILLANCE
Original Article IMPACT OF IMPROVED TREATMENT SUCCESS ON THE PREVALENCE OF TB IN A RURAL COMMUNITY BASED ON ACTIVE SURVEILLANCE P. G. Gopi, R. Subramani, V. Chandrasekaran, T. Santha and P. R. Narayanan
More informationRamesh P. M.*, Saravanan M.
International Journal of Advances in Medicine Ramesh PM et al. Int J Adv Med. 2018 Jun;5(3):561-565 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20181663
More informationOriginal Article. Karanjekar VD, Lokare PO 1, Gaikwad AV 2, Doibale MK 3, Gujrathi VV 2, Kulkarni AP 4. Abstract. Introduction
Original Article Treatment Outcome and Follow up of Tuberculosis Patients Put on Directly Observed Treatment Short course Under Rural Health Training Center, Paithan, Aurangabad in India Karanjekar VD,
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationRevised National Tuberculosis Control Programme
Revised National Tuberculosis Control Programme 2015 C e n t r a l T B D i v i s i o n D i r e c t o r a t e G e n e r a l o f H e a l t h S e r v i c e s M i n i s t r y o f H e a l t h & F a m i l y
More informationISSN X (Print)
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2016; 4(3C):836-841 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationNATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis
NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis Patients registered during quarter* of 20 Name of area No.# Name of the Reporter Signature:
More informationKey Words: Pulmonary Tuberculosis; Smear and Culture Findings; India METHODS
Original Article EVALUATION OF BACTERIOLOGICAL DIAGNOSIS OF SMEAR POSITIVE PULMONARY TUBERCULOSIS UNDER PROGRAMME CONDITIONS IN THREE DISTRICTS IN THE CONTEXT OF DOTS IMPLEMENTATION IN INDIA C.N. Paramasivan
More informationFREQUENCY OF SECONDARY MULTI DRUG RESISTANCE PULMONARY TUBERCULOSIS IN CATEGORY-II FAILURE PATIENTS
ORIGINAL ARTICLE FREQUENCY OF SECONDARY MULTI DRUG RESISTANCE PULMONARY TUBERCULOSIS IN CATEGORY-II FAILURE PATIENTS Abdul Sattar Khan*, Raza Ullah**, Zafar Iqbal***, Shahida Naz**** *District Specialist,
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationVidarbha Journal of Internal Medicine Volume 22 January 2017
Original Article Outcome of TB in TB-HIV co-infection under RNTCP and Factors affecting Outcome - A Retrospective Analysis 1 2 3 4 5 Radha Munje, Sanjay Gaur, Jitendra Jeswani, Punit Jhawar, Sadaf Khatib
More informationMulti-drug Resistant Tuberculosis in Rajshahi District
TAJ December 2005; Volume 18 Number 2 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Original Article Multi-drug Resistant Tuberculosis in Rajshahi District M Wasim Hussain, 1 M Azizul
More informationDRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION
JOURNAL OF PREVENTIVE MEDICINE 2008; 16(3-4): 3-9 Inviting Editorial DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION Harshad Thakur Centre for Health Policy, Planning and Management,
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
More informationTreatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
More informationOverview of the Presentation
Overview of the Presentation Definitions(TBCase, MDR-TB & XDR-TB) Global Tuberculosis (TB,HIV/TB,MDR & XDR)Scenario & Trend Risk factor for TB Natural history of TB Types of TB & Trends of Extra Pulmonary
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationResearch Article. Saibal Moitra 1, Sukanta Sen 2 *, Prasanta Das 3, Mridula Bose 4. DOI: / ijrms
International Journal of Research in Medical Sciences Moitra S et al. Int J Res Med Sci. 2014 Aug;2(3):1121-1126 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: 10.5455/2320-6012.ijrms20140896
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Short Communication Awareness of Medical Interns Regarding Recent Guidelines of Revised National Tuberculosis Control
More informationManagement of Drug-resistant Tuberculosis (DR-TB)
Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationISSN X (Print) Research Article. *Corresponding author Dr. Ramesh B
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2013; 1(6):739-744 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationTitle: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.
Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant
More informationRevised National Tuberculosis Control Programme
Revised National Tuberculosis Control Programme 1 OUTLINE OF PRESENTATION Introduction Burden Of The Disease Evolution Of RNTCP Goals And Objectives Of RNTCP DOTS Stop TB Strategy Organization RNTCP Endorsed
More informationInternational Journal of Pharma and Bio Sciences
Research Article Microbiology International Journal of Pharma and Bio Sciences ISSN 0975-6299 ANTI-TUBERCULOSIS DRUG RESISTANCE IN PREVIOUSLY UNTREATED PULMONARY TUBERCULOSIS PATIENTS IN PUNE, INDIA MICHAEL
More informationChemotherapy of tuberculosis in Hong Kong: a consensus statement
Chemotherapy of tuberculosis in Hong Kong MEDICAL PRACTICE Chemotherapy of tuberculosis in Hong Kong: a consensus statement The Tuberculosis Control Coordinating Committee of the Hong Kong Department of
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received
More informationPrinciple of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos
Principle of Tuberculosis Control CHIANG Chen-Yuan MD, MPH, DrPhilos Estimated global tuberculosis burden 2015 an estimated 10.4 million incident cases of TB (range, 8.7 million 12.2 million) 142 cases
More informationTB infection control: overview and importance
TB infection control: overview and importance John Ferguson, Newcastle, NSW Infectious Diseases & Microbiology jferguson@hnehealth.nsw.gov.au Goroka Hospital, September 2014 Patterns of TB disease Latent
More informationTreatment Outcome of Pulmonary and Extra Pulmonary Tuberculosis Patients in TB and Chest Disease Hospital DOT Centre, Goa, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 4 (2016) pp. 437-441 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.504.051
More informationUpdate on Management of
Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationStudy of treatment outcome of tuberculosis among HIV co-infected patients: a cross sectional study in Aurangabad city, Maharashtra
International Journal of Community Medicine and Public Health Warkari PD et al. Int J Community Med Public Health. 2017 Dec;4(12):4466-4471 http://www.ijcmph.com pissn 2394-6032 eissn 2394-6040 Original
More informationDrug resistance in tuberculosis in India
Review Article Indian J Med Res 120, October 2004, pp 377-386 Drug resistance in tuberculosis in India C.N. Paramasivan & P. Venkataraman Tuberculosis Research Centre (ICMR),Chennai, India Received October
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationMarcos Burgos, MD has the following disclosures to make:
Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures
More informationPredicting outcomes and drug resistance with standardised treatment of active tuberculosis
Eur Respir J 21; 36: 87 877 DOI: 1.1183/931936.15179 CopyrightßERS 21 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis O. Oxlade*,#, K. Schwartzman*,#, M. Pai*,#,
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationTB the basics. (Dr) Margaret (DHA) and John (INZ)
TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2
More informationThe emerging threat of multidrug resistant TB: Global and local challenges and solutions
Summary of IOM-ASSAf Workshop on: The emerging threat of multidrug resistant TB: Global and local challenges and solutions Salim S. Abdool Karim Pretoria - March, 2010 Why this workshop? Why is it on MDR
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationPediatric tuberculosis (i.e., Tuberculosis
G U I D E L I N E S Updated National Guidelines for Pediatric Tuberculosis in India, 2012 ASHOK KUMAR, DEVESH GUPTA, SHARATH BURUGINA NAGARAJA, *VARINDER SINGH, # GR SETHI AND JAGADISH PRASAD From Central
More informationInformation Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis
Information Note WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis In order to ensure that the upcoming comprehensive revision of WHO policies on treatment
More informationAN OVERVIEW ON DRUG RESISTANT TUBERCULOSIS IN INDIA
Review Article Ind. J. Tub., 1998, 45, 73 AN OVERVIEW ON DRUG RESISTANT TUBERCULOSIS IN INDIA C.N. Paramasivan Introduction Tuberculosis remains one of the major public health problems in India. It has
More informationIndex No. All five (05) questions should be answered. All questions carry equal marks.
POSTGRADUATE INSTITUTE OF MEDICINE UNIVERSITY OF COLOMBO POSTGRADUATE DIPLOMA IN TUBERCULOSIS & CHEST DISEASES EXAMINATION - MAY 2016 Date :- 4 th May 2016 PAPER I CASE HISTORIES Time :- 9.00 a.m. -11.00
More informationMonica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale
Randomized Trial of lsoniazid as Secondary Prophylaxis for Prevention of Recurrent Pulmonary Tuberculosis in HIV-positive Patients After One Episode of Tuberculosis Monica Manandhar A. Study Purpose and
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationDetection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 1543-1549 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.185
More informationIndian Journal of Basic and Applied Medical Research; June 2016: Vol.-5, Issue- 3, P
Original article: Study of pulmonary and extra pulmonary Tuberculosis in HIV patients in co-relation to their CD4 count in Vijayapura district, Karanataka 1Dr. Ravi Totad, 2 Dr. S.L. Lakkannavar, 3 Dr.
More informationSputum grading as a predictor of treatment outcome of new sputum smear positive tuberculosis patients in Khammam Tuberculosis Unit
Sputum grading as a predictor of treatment outcome of new sputum smear positive tuberculosis patients in Khammam Tuberculosis Unit Shankar Reddy Dudala 1, Raghotham Reddy K 2, Chandrasekhar Reddy Bolla
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationSHORT COURSE CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS IN CHILDREN
SHORT COURSE CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS IN CHILDREN Padma Ramachandran, A.S. Kripasankar and M. Duraipandian* chest radiograph suggestive of tuberculosis. There are a number of reports on
More informationEtiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition
Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis
More informationAkujobi CN, Okoro CE, Anyabolu AE, Okonkwo RC, Onwunzo MC and Chukwuka CP
Akujobi CN, Okoro CE, Anyabolu AE, Okonkwo RC, Onwunzo MC and Chukwuka CP Tuberculosis (TB) is the most common opportunistic infection in Human Immunodeficiency Virus (HIV)-infected patients. 1 HIV-infected
More informationActive community surveillance of the impact of different tuberculosis control measures, Tiruvallur, South India,
Int. J. Epidemiol. Advance Access published October 9, 2006 Published by Oxford University Press on behalf of the International Epidemiological Association Ó The Author 2006; all rights reserved. International
More informationISSN X (Print) Research Article
Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2014; 2(1C):269-273 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
More informationSMEAR MICROSCOPY AS SURROGATE FOR CULTURE DURING FOLLOW UP OF PULMONARY MDR-TB PATIENTS ON DOTS PLUS TREATMENT
Original Article SMEAR MICROSCOPY AS SURROGATE FOR CULTURE DURING FOLLOW UP OF PULMONARY MDR-TB PATIENTS ON DOTS PLUS TREATMENT R. Sarin 1, R. Singla 2, P. Visalakshi 3, A. Jaiswal 4, M.M. Puri 4, Khalid
More informationANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM
ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM The form and content of the explanatory note is to: Inform those responsible for completing the DMR 164 Reporting Form - as to
More informationBasic Overview of Tuberculosis Epidemiology in the Czech Republic in 2015
Centre for the development of technology platform used in registries of the National Health Information System, modernisation of data mining within these registries and extending their information capacity.
More informationTreatment outcomes and survival based on drug resistance patterns in multidrug-resistant
Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis Doh Hyung Kim, Hee Jin Kim, Seung-Kyu Park, Suck-Jun Kong, Young Sam Kim, Tae-Hyung Kim, Eun Kyung
More informationTWICE WEEKLY STREPTOMYCIN AND ISONIAZID REGIMEN WITHOUT SUPERVISION. J.L. BHATIA AND BALDEV RAJ (From Medical College, Amritsar)
Introduction TWICE WEEKLY STREPTOMYCIN AND ISONIAZID REGIMEN WITHOUT SUPERVISION J.L. BHATIA AND BALDEV RAJ (From Medical College, Amritsar) The Tuberculosis Chemotherapy Research Centre, Madras, have
More informationPilot Study of Twice-weekly Therapy for Pulmonary Tuberculosis in Taiwan
Volume 110 Number 7 July 2011 Enterovirus 71 vaccine: When will it be available? GRP78 in embryonic development and neurological disorders Directly observed therapy for Tuberculosis patients in Taiwan
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationMolecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.
Title Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium. Author(s) Ho, PL; Yam, WC; Leung, CC; Yew, WW; Mok, TYW; Chan, KS; Tam, CM Citation Hong Kong Medical
More informationRadiological manifestations of HIV Pulmonary Tuberculosis co - infection
Original article Radiological manifestations of HIV Pulmonary Tuberculosis co - infection Kumar Adesh 1 (MD), Gautam Kumar Aditya 2 (MD), Gupta Kumar Ashish 3 (MD), Yadav Prashant 4 (MD), Bhattacharya
More informationSputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation?
Journal of Antimicrobial Chemotherapy (27) 59, 794 798 doi:.93/jac/dkm25 Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? Jesús
More informationHomeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis
Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis Presenting author: Dr. Neha Sharma Authors: S. Sharma, RG Sharma, Chand K NMP Medical Research Institute,
More informationDRUG RESISTANCE IN TUBERCULOSIS
DRUG RESISTANCE IN TUBERCULOSIS INTRODUCTION Up to 50 million people may be infected with drug-resistant resistant TB.* Hot zones of MDR-TB such as Russia, Latvia, Estonia, Argentina and the Dominican
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationBasic Overview of Tuberculosis Epidemiology in the Czech Republic in 2017
Centre for the development of technology platform used in registries of the National Health Information System, modernisation of data mining within these registries and extending their information capacity.
More informationPATTERNS OF DRUG RESISTANCE AND RFLP ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED FROM RECURRENT TUBERCULOSIS PATIENTS IN SRI LANKA
PATTERNS OF DRUG RESISTANCE AND RFLP ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED FROM RECURRENT TUBERCULOSIS PATIENTS IN SRI LANKA DN Magana-Arachchi 1, AJ Perera 1, V Senaratne 2 and NV Chandrasekharan
More informationBiology and Medicine
eissn: 09748369 Diagnosis of pulmonary tuberculosis by smear microscopy and culture in a tertiary health care facility Biology and Medicine SI Khatib, MT Williamson, R Singh, JM Joshi Accepted: 28 th Feb
More informationCOMMONEST CAUSE OF INITIATING CATEGORY II DIRECTLY OBSERVED TREATMENT SHORT COURSE IN TUBERCULOSIS PATIENTS
Original Research Article DOI - 10.26479/2016.0204.06 COMMONEST CAUSE OF INITIATING CATEGORY II DIRECTLY OBSERVED TREATMENT SHORT COURSE IN TUBERCULOSIS PATIENTS Manthan Mehta 1, Cherylann Melo 2, Shital
More informationTB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks
1 TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks 2 Page 1 4 NHS Lothian Infection Prevention and Control Study Day On
More informationRole of gene Xpert MTB/ RIF assay in diagnosis of Tubercular Pleural Effusion
International Journal of Current Research in Medical Sciences ISSN: 2454-5716 P-ISJN: A4372-3064, E -ISJN: A4372-3061 www.ijcrims.com Original Research Article Volume 3, Issue 5-2017 Role of gene Xpert
More informationA study on non-compliance in tuberculosis cases towards the directly observed treatment short course under RNTCP in Kanpur Nagar
International Journal of Community Medicine and Public Health Srivastava K et al. Int J Community Med Public Health. 2017 Dec;4(12):4485-4489 http://www.ijcmph.com pissn 2394-6032 eissn 2394-6040 Original
More information11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction
SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More informationM ultidrug resistant (MDR) tuberculosis (TB) has
1106 ORIGINAL ARTICLE Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome H S Schaaf, K Shean, P R Donald... See end of article for authors affiliations...
More informationProfile of HIV Associated Tuberculosis at a Tertiary Institute in Setting of Free Anti-Retroviral Therapy
Original Article Profile of HIV Associated Tuberculosis at a Tertiary Institute in Setting of Free Anti-Retroviral Therapy Upasna Agarwal *, Amitabh Kumar **, Digamber Behera *** Abstract Setting: With
More informationDIAGNOSTIC YIELD OF FIBER-OPTIC BRONCHOSCOPY IN SPUTUM SMEAR NEGATIVE AND RADIOLOGICALLY SUSPECTED OLD CASES PULMONARY TUBERCULOSIS
Original Research Article International Journal of Medical Science and Education pissn- 2348 4438 eissn-2349-3208 DIAGNOSTIC YIELD OF FIBER-OPTIC BRONCHOSCOPY IN SPUTUM SMEAR NEGATIVE AND RADIOLOGICALLY
More informationClarithromycin-resistant Mycobacterium Shinjukuense Lung Disease: Case Report and Literature Review
Showa Univ J Med Sci 28 4, 373 377, December 2016 Case Report Clarithromycin-resistant Mycobacterium Shinjukuense Lung Disease: Case Report and Literature Review Makoto HAYASHI 1, Satoshi MATSUKURA 1,
More informationTreatment of lymph node tuberculosis a randomized clinical trial of two 6-month regimens
Tropical Medicine and International Health doi:10.1111/j.1365-3156.2005.01493.x volume 10 no 11 pp 1090 1098 november 2005 Treatment of lymph node tuberculosis a randomized clinical trial of two 6-month
More informationPLASMA COPPER AND ZINC LEVELS IN PULMONARY TUBERCULOSIS
PLASMA COPPER AND ZINC LEVELS IN PULMONARY TUBERCULOSIS B.K. KHANNA, R. KUMAR, P.K. MUKERJI,* A.R. CHOWDHURY AND V,P. KAMBOJ** Summary : A study of plasma copper and zinc level was conducted in 46 normal
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationTB Clinical Guidelines: Revision Highlights March 2014
TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationTRENDS IN THE PREVALENCE OF PULMONARY TUBERCULOSIS OVER A PERIOD OF SEVEN AND HALF YEARS IN A RURAL COMMUNITY IN SOUTH INDIA WITH
168 Original Article TRENDS IN THE PREVALENCE OF PULMONARY TUBERCULOSIS OVER A PERIOD OF SEVEN AND HALF YEARS IN A RURAL COMMUNITY IN SOUTH INDIA WITH DOTS @ C. Kolappan 1, R. Subramani 1, S. Radhakrishna
More information